Evidence map›Paper›PMID 36613987›Full record

ArticleInternational journal of molecular sciences2022

Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels of

Maria Jesus Alvarez-Cubero, Elena Arance, Esperanza de Santiago, Pilar Sanchez, Maria Rosario Sepúlveda, Raquel Marrero, Jose Antonio Lorente, Jose Maria Gonzalez-Cabezuelo, Sergio Cuenca-Lopez, Jose Manuel Cozar and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Prostate Cancer-Research Advances in Early Detection.Journal of clinical medicine · 2025
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Maria Jesus Alvarez-CuberoGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0002-5492-9355
Elena AranceGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0003-0963-079X
Esperanza de SantiagoGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0001-5170-927X
Pilar SanchezDepartment of Biochemistry and Molecular Biology III, Faculty of Medicine, University of Granada, PTS Granada, 18016 Granada, Spain.
Maria Rosario SepúlvedaDepartment of Cell Biology, Faculty of Sciences, University of Granada, Avenida de la Fuente Nueva S/N CP, 18071 Granada, Spain.ORCID 0000-0002-2375-5866
Raquel MarreroGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.
Jose Antonio LorenteGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0002-9892-7386
Jose Maria Gonzalez-CabezueloMeridiem Seeds, Research and Development Department, 04710 Almería, Spain.ORCID 0000-0003-2535-4203
Sergio Cuenca-LopezGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0003-3805-1228
Jose Manuel CozarUrology Department, Virgen de las Nieves Hospital, 18014 Granada, Spain.
Fernando Vazquez-AlonsoUrology Department, Virgen de las Nieves Hospital, 18014 Granada, Spain.ORCID 0000-0003-3819-3832
Luis Javier Martinez-GonzalezGENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Genomics Unit, PTS Granada, Avenida de la Ilustración 114, 18016 Granada, Spain.ORCID 0000-0003-2202-0662
Universidad de Granada · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESHospital Universitario Virgen de las Nieves · ES

Funding

Andalusian Health Service PI-0319-2018Urology Research Foundation (FIU) Leonardo de la Peña 2020
6 · The paper itself

Abstract

The management and screening of prostate cancer (PC) is still the main problem in clinical practice. In this study, we investigated the role of aggressiveness genetic markers for PC stratification. We analyzed 201 plasma samples from PC patients and controls by digital PCR. For selection and validation, 26 formalin-fixed paraffin-embedded tissues, 12 fresh tissues, and 24 plasma samples were characterized by RNA-Seq, immunochemistry, immunofluorescence, Western blot, and extracellular-vesicles analyses. We identified three novel non-invasive biomarkers; all with an increased expression pattern in patients (

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAntigens, NeoplasmBiomarkers, TumorFollow-Up StudiesHumansMaleROC CurveS100 Calcium-Binding Protein A4Antigens, NeoplasmBiomarkers, TumorProstate-Specific AntigenS100A4 protein, humanS100 Calcium-Binding Protein A4aggressivenessbiomarkerliquid biopsyprostate cancer

Identifiers

PMID36613987
PMCPMC9820153
OpenAlexW4313328775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.